OncoCyte (NASDAQ:OCX) Now Covered by StockNews.com

Equities researchers at StockNews.com initiated coverage on shares of OncoCyte (NASDAQ:OCX) in a research note issued to investors on Tuesday. The brokerage set a “sell” rating on the stock.

Separately, Needham & Company LLC reiterated a “buy” rating and issued a $4.25 price target on shares of OncoCyte in a research report on Wednesday, November 13th.

OncoCyte Stock Down 3.8 %

Shares of NASDAQ OCX opened at $2.44 on Tuesday. OncoCyte has a one year low of $2.00 and a one year high of $4.19. The stock’s fifty day moving average price is $2.95 and its two-hundred day moving average price is $2.98.

OncoCyte (NASDAQ:OCX) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.98) EPS for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.54). OncoCyte had a negative return on equity of 269.32% and a negative net margin of 6,122.29%. The business had revenue of $0.12 million for the quarter. During the same quarter last year, the company posted ($0.57) earnings per share.

Insider Activity at OncoCyte

In other news, major shareholder Broadwood Partners, L.P. purchased 1,315,339 shares of OncoCyte stock in a transaction that occurred on Wednesday, October 2nd. The shares were acquired at an average price of $2.95 per share, for a total transaction of $3,880,250.05. Following the transaction, the insider now owns 6,244,405 shares of the company’s stock, valued at approximately $18,420,994.75. The trade was a 26.69 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CFO Andrea S. James acquired 33,670 shares of the stock in a transaction on Wednesday, October 2nd. The shares were purchased at an average price of $2.97 per share, with a total value of $99,999.90. Following the completion of the transaction, the chief financial officer now owns 33,670 shares of the company’s stock, valued at approximately $99,999.90. This represents a ? increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.58% of the stock is owned by insiders.

Institutional Trading of OncoCyte

An institutional investor recently raised its position in OncoCyte stock. Geode Capital Management LLC boosted its stake in OncoCyte Co. (NASDAQ:OCX) by 12.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 103,980 shares of the company’s stock after purchasing an additional 11,289 shares during the period. Geode Capital Management LLC owned about 0.62% of OncoCyte worth $296,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 55.35% of the company’s stock.

OncoCyte Company Profile

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.